Sasaki H, Takada K, Terashima Y, Ekimoto H, Takahashi K, Tsuruo T, Fukushima M
Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan.
Gynecol Oncol. 1991 Apr;41(1):36-40. doi: 10.1016/0090-8258(91)90251-y.
The antitumor activity of delta 7-prostaglandin A1 (delta 7-PGA1) or delta 12-prostaglandin J2 (delta 12-PGJ2) on human ovarian cancer cell lines resistant to cisplatin (CDDP), doxorubicin (ADR), and L-phenylalanine mustard (l-PAM) was studied in vitro. A2780AD, A2780 (parent cells of A2780AD), 2008DDP, and 2008 cells (parent cells of 2008DDP) were used. The antitumor activities of the drugs were defined with 50% inhibitory concentration (IC50) estimated from growth inhibition curves, which were obtained by an indirect colorimetric method. Drug-resistance ratios obtained from IC50 values, by comparing A2780AD and A2780 cells, were 62.5 for ADR, 4.6 for CDDP, 4.9 for l-PAM, 1.5 for delta 7-PGA1, and 1.8 for delta 12-PGJ2. Those obtained by comparing 2008DDP and 2008 cells were 1.1 for ADR, 16.0 for CDDP, 2.9 for l-PAM, 2.3 for delta 7-PGA1, and 3.2 for delta 12-PGJ2. Thus some human ovarian cancer cells resistant to ADR, CDDP, and l-PAM remain sensitive to antitumor PGs.
在体外研究了δ7-前列腺素A1(δ7-PGA1)或δ12-前列腺素J2(δ12-PGJ2)对顺铂(CDDP)、阿霉素(ADR)和L-苯丙氨酸氮芥(l-PAM)耐药的人卵巢癌细胞系的抗肿瘤活性。使用了A2780AD、A2780(A2780AD的亲本细胞)、2008DDP和2008细胞(2008DDP的亲本细胞)。通过间接比色法获得生长抑制曲线,根据该曲线估算50%抑制浓度(IC50)来确定药物的抗肿瘤活性。通过比较A2780AD和A2780细胞的IC50值得到的耐药比,ADR为62.5,CDDP为4.6,l-PAM为4.9,δ7-PGA1为1.5,δ12-PGJ2为1.8。通过比较2008DDP和2008细胞得到的耐药比,ADR为1.1,CDDP为16.0,l-PAM为2.9,δ7-PGA1为2.3,δ12-PGJ2为3.2。因此,一些对ADR、CDDP和l-PAM耐药的人卵巢癌细胞对抗肿瘤前列腺素仍敏感。